Pharmaceutical care in transplant patients in a university hospital: pharmaceutical interventions by Martins, Bruna Cristina Cardoso et al.
*Correspondence: B. C. C. Martins. Hospital Universitário Walter Cantídio, 
Universidade Federal do Ceará. Rua Capitão Francisco Pedro, 1290. Rodolfo 
Teófilo, 60430-370 – Fortaleza – CE, Brasil. E-mail: bbrunacristina@hotmail.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 49, n. 4, oct./dec., 2013
Pharmaceutical care in transplant patients in a university hospital: 
pharmaceutical interventions
Bruna Cristina Cardoso Martins1,*, Thalita Rodrigues de Souza2, Ângela Maria Pita Tavares Luna3, 
Marta Maria de França Fonteles4, Paulo Yuri Milen Firmino4, Paula Frassinetti Castelo Branco 
Camurça Fernandes5, José Huygens Parente Garcia6, Cláudia Maria Costa de Oliveira7, Eugenie 
Desirèe Rabelo Néri8
1 Multidisciplinary Residency in Transplantation,University Hospital Walter Cantídio, Fortaleza, CE, Brazil, 2Kidney 
Transplant Unit, University Hospital Walter Cantídio, Fortaleza, CE, Brazil, 3Satellite Pharmacy of Surgical Stations, 
University Hospital Wálter Cantídio, Fortaleza, CE, Brazil, 4Post-Graduation Program in Pharmaceutical Sciences, Federal 
University of Ceará, Fortaleza, CE, Brazil, 5University Hospital Walter Cantídio, Fortaleza, CE, Brazil, 6Head of Liver 
Transplant Unit, University Hospital Walter Cantídio, Fortaleza, CE, Brazil, 7Kidney Transplant Unit, University Hospital 
Walter Cantídio, Fortaleza, CE, Brazil, 8University Hospitals of Federal University of Ceará, Fortaleza, CE, Brazil
A descriptive and prospective study was conducted on the pharmaceutical care in the post-transplant 
outpatient clinic of Hospital Universitario Walter Cantidio of Universidade Federal do Ceará (HUWC/
UFC), in Fortaleza- Ceará in the period of April to October of 2011. The aim of the present study was to 
describe the pharmaceutical interventions performed in a Pharmaceutical Care service structured in the 
liver and kidney transplant outpatient clinic of an academic hospital. The Pharmaceutical interventions 
(PI) were classified according to Sabater et al.(2005), with significance based on Riba et al.(2000) and the 
Negative Outcomes associated with Medication (NOM) established at the Third Consensus of Granada. 
Statistical analyses were performed using the Epi Info v.3.5.1 program and hypothesis tests were done 
with the SigmaPlot v.10.0 program. A chi-squared (X²) test was utilized for statistical analysis of the 
sample. A total of 97 patients were followed, where 54 problems related to medications were identified and 
139 PI performed. The main PI were in education of the patient about treatment (n=111; 80%) (p<0.05), 
while the significance of all interventions were appropriate, where 83.4% (n=116) of PI performed in the 
study period were shown to be “significant” (p<0.05). Through pharmaceutical care, the pharmacist is 
capable of monitoring the pharmacotherapeutic treatment and intervening when necessary, while being 
part of the multiprofessional team caring for the transplant patient.
Uniterms: Pharmaceutical care. Pharmaceutical interventions. Liver transplant/pharmaceutical 
interventions. Kidney transplant/pharmaceutical interventions. Patient safety. Pharmacotherapeutic 
treatment/monitoring.
Trata-se de um estudo de descritivo e prospectivo, realizado durante o atendimento farmacêutico nos 
ambulatórios de pós-transplante do Hospital Universitário Walter Cantídio da Universidade Federal do 
Ceará (HUWC/UFC), em Fortaleza-Ceará no período de abril a outubro de 2011. O presente trabalho 
objetiva apresentar as intervenções farmacêuticas realizadas em um serviço de Atenção Farmacêutica 
(ATENFAR) estruturado nos ambulatórios do transplante hepático e renal de um Hospital Universitário. 
As intervenções farmacêuticas (IF) foram classificadas de acordo com Sabater et al.(2005), a 
significância baseadas em Riba et al.(2000) e os Resultados Negativos associados a Medicamentos 
(RNM) fundamentados no Terceiro Consenso de Granada. As análises estatísticas foram realizadas no 
programa Epi Info v.3.5.1 e os testes de hipótese foram feitos no programa SigmaPlot v.10.0. O teste 
estatístico utilizado para análise da amostra foi o qui-quadrado (X²). Foram acompanhados 97 pacientes, 
identificados 54 problemas relacionados aos medicamentos e realizadas 139 intervenções farmacêuticas. 
As principais IF realizadas foram na educação do paciente sobre o tratamento (n=111; 80%) (p<0,05), 
já enquanto a significância todas as intervenções foram apropriadas, sendo que 83,4% (n=116) das IF 
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realizadas no período do estudo mostram ser “significantes” (p<0,05). O farmacêutico, através do exercício 
da ATENFAR, é capaz de monitorar o tratamento farmacoterapêutico e intervir, quando necessário, 
integrando-se a equipe multiprofissional no cuidado ao paciente transplantado.
Unitermos: Atenção farmacêutica. Intervenção farmacêutica. Fígado/transplante/intervenção 
farmacêutica. Rim/transplante/intervenção farmacêutica. Paciente/segurança. Tratamento 
farmacoterapêutico/monitoramento.
INTRODUCTION
The history of organ transplantation in Brazil began 
1960s, when the first kidney transplant was performed 
in1964 in Rio de Janeiro. In 1985, the first liver transplant 
was successfully carried out in Hospital das Clínicas 
da Universidade de São Paulo (Borges et al., 2010). 
The state of Ceará featured prominently in the country 
when 1037 transplants were conducted in the period of 
January to November of 2011, including 218 renal and 
131 liver transplants (Ceará, 2011). In all Brazil, Hospital 
Universitario Walter Cantidio holds third place in liver 
transplants, just behind Hospital Albert Einstein (SP) and 
Hospital das Clínicas da Universidade de São Paulo. The 
Renal Transplant Service of HUWC/UFC is also a pioneer 
in this area, since the first renal transplant in HUWC was 
performed in 1977, the first in Ceará and in the Northeast 
region (HUWC, 2011).
Liver transplant is indicated for patients who have 
advanced hepatic disease, since at this stage there are 
metabolic alterations, malnutrition, loss of muscle mass 
and function, respiratory alterations and other symptoms 
related to liver disease, where the combination of these 
factors interfere negatively with daily life activities and 
in the quality of life of these individuals (Barcelos et al., 
2008). Renal transplant is one of the most recommended 
treatment and rehabilitation modalities for patients with 
chronic renal insufficiency, because it offers the patient 
a better quality of life, a possible reduction in risk of 
mortality, depending on the characteristics of the patient, 
and lower cost than dialysis. However, the choice for this 
type of treatment should take into account the individual 
characteristics of the patients, that is, demographic and 
co-morbidity factors, because each treatment modality has 
advantages and disadvantages (Cunha et al., 2007). After 
the transplant, the patient must adhere to a therapeutic 
regimen that includes taking immunosuppressants 
throughout life and frequent doctor visits and laboratory 
tests (Berquist et al., 2008). Non-adherence to treatment 
can result in graft rejection, which is a complicating factor 
in post-transplant care.
The transplant, although affording a better quality 
of life, demands a differentiated lifestyle in relation to 
eating, hygiene, medications and health precautions. 
A large portion of transplant patients, besides taking 
immunosuppressive drugs, concomitantly receive 
treatment for chronic diseases such as hypertension, 
diabetes and dyslipidemia and utilize prophylactic 
such as antibiotics, antifungals and antivirals. This 
polytherapy increases the risk of adverse reactions and 
drug interactions, besides difficulties in the utilization of 
medications (Wang et al., 2008).
A multidisciplinary approach is essential to 
guarantee adequate care of the transplant patient, 
particularly through the clinical duties of the pharmacist 
in the context of clinical pharmacy and pharmaceutical 
care. This can help reduce the risk of morbidities caused 
by pharmacotherapy, preventing treatment failure and 
complications of combined therapy (Hernanz, 2007).
Pharmaceutical care emerged from the development 
of clinical pharmacy practice, with the inclusion of a human 
component (Brasil, 2007). At the end of the 1980s, Hepler 
published a series of articles that established the necessity 
of changing the paradigm of professional pharmacy 
practice. These papers culminated in the publication of 
Opportunities and Responsabilities in Pharmaceutical 
Care (1990), which together with Strand, considered the 
beginning of a new paradigm – Pharmaceutical Care 
(Castro et al., 2006). The new professional practice led 
to closer relations between pharmacists and physicians, 
with the common objective of increasing the efficacy of 
drug treatment.
Systematic reviews report the positive findings with 
regard to the activities of clinical pharmacists in hospital 
teams (Kaboli et al., 2006; Wang, 2008). Pharmaceutical 
care practice demands that the professional takes part in 
a process in which he/she cooperates with the patient and 
other health care professionals, with the primary function 
of identifying drug-related problems (DRP), real or 
potential, as well as resolving the real ones and preventing 
the potential ones (Castro et al., 2006).
In Brazil, several studies involving Pharmaceutical 
Care for groups of patients with chronic diseases were 
conducted through the years. Many of them were able 
to show the benefits of this practice within the Brazilian 
health system, like the review realized by Simoni (2009), 
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which showed that the process of solving Drug Related 
Problems in a Pharmaceutical Care service may aid the 
blood pressure control in non-controlled hypertensive 
individuals from community pharmacies. Besides, the 
meta-analysis conducted by Collins et al. (2011) and the 
study carried out by Lyra Jr et al. (2011) suggested that 
the pharmacist’s intervention may be considered as a 
fundamental tool at the diabetes care and cardiovascular 
risk management.
Due to the benefits shown by the participation 
of the pharmacist on clinical and assistential level, the 
Pharmaceutical Care for special groups of patients/
users, especially in the SUS network, was included in the 
National Agenda of Science, Technology and Innovation 
for Health (Brasil, 2007). In 2001, a group of institutions 
concerned about the development of Pharmaceutical Care 
in Brazil constituted the Pharmaceutical Care Management 
Group under the coordination of the Pan-American Health 
Organization (PAHO). From the activities undertaken 
by this group resulted on a Brazilian Pharmaceutical 
Care Consensus proposal, being considered as it follows 
“a pharmaceutical practice model, developed in the 
pharmaceutical assistance context, which comprehends 
attitudes, ethical values, behaviors, skills, commitments 
and co-responsibilities at disease prevention, health 
promotion and recovery integrated with the professional 
health team.
Not all drug therapy problems can be identified 
from the medical prescription (Rovers, Currie, 2010). 
In pharmaceutical care, the pharmacist collects and 
organizes additional information to assure that the 
expected therapeutic outcome is achieved with the 
minimal occurrence of NOM. Through the practice of 
pharmaceutical care, the pharmacotherapeutic monitoring 
of patients is achieved and pharmaceutical interventions 
are performed, which are defined as all the activities in 
which the pharmacist actively participates, such as in 
decision making in the therapy of patients and also in the 
evaluation of results, thereby contributing to the increase 
in the efficacy of pharmacotherapy and decreasing its risks 
(Amaral, Amaral, Provin, 2008).
Drug Related Problems (DRP) were defined as 
any undesirable events experienced by the patient that 
involve or are suspected of involving medication and that 
interfere actually or potentially with an expected result in 
the treatment of the patient. Interference is not only limited 
to diseases and symptoms, but can also be any problem 
related to psychological, physiological, sociocultural or 
economic aspects. These DRP can cause or lead to the 
appearance of a NOM, where these effects on the health 
of the patient are not consistent with the objectives of 
the pharmacotherapy and are associated with the use of 
medications (Dader, Muñoz, Martinez-Martinez, 2008).
The selection of groups of patients is indispensable 
in Pharmaceutical Care, since it is not possible to analyze 
all the groups (Amaral, Amaral, Provin, 2008). The 
choice of target patients, which is, group of patients for 
whom the service is structured with the aim of carrying 
out necessary interventions, gives the pharmacist 
a greater impact in disease prevention and health 
promotion. This is done through counseling on the use 
of medications according to the desired results, with the 
purpose of reducing the occurrence of adverse reactions 
to medications and guaranteeing adherence to treatment 
(WHO, 2006). A study by Chisholm et al. (2001) showed 
that a multidisciplinary team approach that included a 
clinical pharmacist in the care of post-transplant patients 
was beneficial to improving their adherence to treatment.
The aim of the present study was thus to describe 
the pharmaceutical interventions performed in a 
pharmaceutical care service structured in the liver and 
kidney transplant outpatient clinic of an academic hospital 
in Ceará, Brazil, along with the pharmacoepidemiological 
profile of the patients seen in the service.
MATERIAL AND METHODS
A descriptive and prospective study was conducted 
during the pharmaceutical care of patients of the outpatient 
clinic for kidney and liver post-transplant care of Hospital 
Universitario Walter Cantidio da Universidade Federal do 
Ceará (HUWC/UFC), in the period of April to October of 
2011. HUWC/UFC is a 243-bed academic hospital with 
broad specialized outpatient services and a complementary 
diagnostic services unit, which offers a high complexity 
level of tertiary health care.
The data were obtained from pharmacotherapeutic 
follow-up charts of patients seen at the kidney and liver 
transplant services, also with review of the patient’s 
medical records. The pharmaceutical care service was 
realized by the resident pharmacists from the transplant 
area along with a pharmacist from the HUWC/UFC 
staff in the liver and kidney transplant ambulatory on a 
weekly basis. All patients who received care during the 
study period were selected P1 2º Revisor). The patients 
included in the study were receiving post-transplant 
ambulatory care, being selected, among them, those 
who received pharmaceutical care. Therefore, it was 
considered a convenience sampling technique. The 
follow-up of these patients was realized during the 
appointments with the pharmacists after being sent by 
the multi-professional health team. The patients were 
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followed-up by the Dader method (Machuca, Fernandez-
Llimos, Faus, 2003). During the study, the clinical 
activities (Pharmacotherapeutic follow-up, Identification 
of DRP and NOM, Pharmaceutical Intervention) were 
carried out by the pharmacist assigned to the kidney and 
liver transplant patients. Serum levels were recorded for 
immunosuppressants utilized by the transplant patients, 
that belonged to the class of calcineurin inhibitors or of 
mTor (mammalian target of rapamycin) inhibitors. Next, 
the post-transplant period of the patient was correlated 
with the serum immunosuppressant level, and comparison 
was made with the protocols established by the kidney 
and liver transplant team, to determine if the patient 
was within the level recommended for the period. The 
levels of calcineurin and mTor inhibitors are determined 
in the follow-up routine of patients and usually utilized 
in determining adherence to treatment in these patients. 
The determination of the serum level precedes each 
appointment scheduled with the physician, being used in 
this study, the mean value of the results on the pharmacist 
appointments.
Pharmaceutical interventions were classified 
according to Sabater et al. (2005) and categorized 
by significance (“significant,” “very significant” and 
“extremely significant”) according to Riba et al. (2000). In 
turn, the NOM followed the Third Consensus of Granada 
(2007) (Figure 1). The medications utilized by the patients 
seen by the service were classified according to the 
Anatomical Therapeutic Chemical (ATC) classification 
system (WHO, 2012).
The Epi Info v.3.5.1 program was used to perform 
the analyses of the data, and hypothesis tests were done 
with SigmaPlot v.10.0. A chi-squared (X²) test was utilized 
for statistical analysis of the sample nominal variable. 
The level of significance considered for the comparative 
analyses was p<0.05. The observations of each variable 
were tabulated together with the presentation of the 
descriptive statistics of quantitative variables, which were 
presented graphically when convenient. In relation to the 
ethical aspects, the study was conducted in accordance 
with the Guidelines and Standards Regulating Research 
involving Humans and was approved by the Committee 
of Ethics in Research of HUWC/UFC under Protocol 
No.111.11.11.
RESULTS
A group of 97 post-transplant patients received 
pharmaceutical care during the study period. The patients 
were predominantly male (58.8%; n=57) with an age range 
of 41 – 60 years (40.3%; n=39), where 35 (n=36.1%) had 
an incomplete primary education and 66 (68%) patients 
were from other localities. A caretaker was involved in 
almost all cases (n=85, 87.6%). The majority of these 
caretakers had a complete secondary education (42.4%; 
n=36), and most were wives (33%; n=28) (Table I).
In the analysis of pharmacotherapeutical profile of 
the medications utilized by the patients (Table II), during 
the at the end of the study period, the mean consumption 
of medications was 7 per patient, where there was a 
prevalence of antineoplastics and immunomodulators 
(Group L) (n=194; 29.3%), followed by medications 
belonging to the group of general antibiotics for systemic 
use (Group J) (n=145; 22%) and medications for the 
digestive tract and metabolism (Group A) (n=132; 20%).
Anatomical Therapeutic Chemical (ATC)
The serum level of immunosuppressants of the 
calcineurin inhibitor class associated with the post-
transplant time of the patient showed that the patients 
who had a liver transplant and were in follow-up in the 
Pharmaceutical Care service were completing on average 
5 months post-transplant and only 8.1% (n=3, p < 0.05) 
had a tacrolimus level at variance with the protocol 
comparing the groups of patients divided according to 
NECESSITY
-Untreated health problem: the patient suffers from a health 
problem associated with the lack of a needed medication;
-Effect of unnecessary medication: the patient suffers from 
a health problem associated with taking a medication that is 
not needed.
EFFECTIVENESS
-Non-quantitative ineffectiveness: the patient suffers from 
a health problem associated with the non-quantitative 
ineffectiveness of the medication;
-Quantitative ineffectiveness: the patient suffers from a health 
problem associated with the quantitative ineffectiveness of 
the medication.
SAFETY
-Non-quantitative safety: the patient suffers from a health 
problem associated with a non-quantitative safety problem 
of the medication;
- Quantitative safety: the patient suffers from a health 
problem associated with a quantitative safety problem of the 
medication.
Source: research group in pharmaceutical care - Universidad 
de Granada (Spain).
FIGURE 1 - Classification of Negative Outcomes associated 
with Medication (NOM) according to the Third Consensus of 
Granada, 2007.
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TABLE I - Epidemiological characteristics of patients seen by 
the Pharmaceutical Care Service for kidney and liver transplant 
patients. April – October/2011, Fortaleza –Ceará
VARIABLE N (%)
SEX
Female - 40 (41.2)
Male - 57 (58.8)
AGE
< 20 years - 10 (10.3)
20 - 40 years - 27 (27.8)
41 - 60 years - 39 (40.3)
> 60 years - 21 (21.6)
EDUCATION
Illiterate - 9 (9.3)
Incomplete primary - 35 (36.1)
Complete primary - 12 (12.4)
Incomplete secondary - 9 (9.3)
Complete secondary - 27 (27.8)
Incomplete higher - 1 (1.0)
Complete higher - 4 (4.1)
ORIGIN
Fortaleza - 31 (32)
Other - 66 (68)
EDUCATION OF 
CARETAKER
Illiterate - 2 (2,3)
Incomplete primary - 17 (20,0)
Complete primary - 17 (20,0)
Incomplete secondary - 6 (7,1)
Complete secondary - 36 (42,4)
Incomplete higher - 1 (1,2)
Complete higher - 6 (7,0)
RELATION OF 
CARETAKER
Wife - 28 (33)
Mother - 13 (15.3)
Daughter - 10 (11.7)
Sister - 6 (7.0)
Husband - 4 (4.7)
Cousin - 4 (4.7)
Niece - 4 (4.7)
Other - 8 (9.5)
Son - 2 (2.3)
Brother - 2 (2.3)
Sister-in-law - 2 (2.3)
Aunt - 2 (2.3)
TABLE II - Medications utilized by the kidney and liver transplant 
patients seen by the Pharmaceutical Care service
MAIN ANATOMICAL GROUPS OF 
ATC SYSTEM *
ATC 
CODE*
N (%)
Digestive tract and metabolism A 132 (20)
Blood and hematopoietic organs B 32 (5)
Cardiovascular system C 70 (10.6)
Urogenital system and sex hormones G 3 (0.4)
Hormones of systemic use, excluding 
sex hormones 
H 79 (12)
General antibiotics for systemic use J 145 (22)
Antineoplastics and 
immunomodulators
L 194 (29.3)
Musculoskeletal system M 1 (0.1)
Central nervous system N 5 (0.7)
TOTAL 661 (100)
April – October/2011, Fortaleza – Ceará.
the serum level, determined during the follow-up period. 
The post-kidney transplant patients were in the period of 6 
months and all patients had a tacrolimus level in agreement 
with the service protocol in the follow-up period (Tables 
III and IV). During follow-up, five patients were on an 
mTOR inhibitor with a level of 6 ng/mL and with on 
average 8 months post-kidney transplant, in agreement 
with the service protocol.
A total of 54 DRP were identified, with 63.0% 
(n=34) in post-kidney transplant and 20% (n=20) in 
post-liver transplant. From the identification of real 
and potential DRP, pharmaceutical interventions were 
performed to prevent possible NOM. The most common 
NOM (Figure 2) were related to untreated health problem 
(n=26; 48.1%) and quantitative ineffectiveness (n=10; 
18.5%). The most frequently used medications were 
involved with NOM: tacrolimus (n= 6; 11.1%); nystatin 
(n=5; 9.2%); and insulin, omeprazol, prednisone, and 
sulfamethoxazole+trimethoprim (n=4; 7.4%).
During the study period, 139 pharmaceutical 
interventions (PI) were performed, mainly on the patient 
(77%; n=108), and of these interventions, 1.4% (n=2) were 
not accepted (Figure 3).
According to the classification by Sabater et 
al.(2005), the main interventions (Table V) were as 
follows: education of the patient regarding treatment 
(n=111; 80%; p<0.05), which showed greater statistical 
significance compared to the intervention groups, notably 
within this classification the interventions performed 
in treatment guidelines (70%; n=95; p<0.05); dose 
of medication (n=15; 11%) with greater frequency in 
the change in dosage of prescribed medication (n=4; 
3%); and pharmacological strategy (n=13; 9%), with 
request for suspending unnecessary medication being 
the most frequent at 7% (n=10) (Table VI). With regard 
to significance, classified according to Farre et al., (não 
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TABLE III - Serum levels of calcineurin inhibitor (Tacrolimus) of liver transplant patients seen by the Pharmaceutical Care Service. 
April – October/2011, Fortaleza – Ceará
LIVER TRANSPLANT 
TIME AFTER 
TRANSPLANT
TACROLIMUS (mean value) 
serum level, ng/mL)
No. OF PATIENTS (%) TACROLIMUS PROTOCOL1 
(serum level, ng/mL)
2nd month 11 3 (8.1) 
p<0.05, X²test
 8 – 10
3rd - 5th month 7 19 (51.4) 6 – 8
≥ 6 months 6 15 (40.5) 4 – 6
TOTAL 37 (100%)
1Clinical protocols of liver transplant service of Walter Cantídio University Hospital – Federal University of Ceará.
TABLE IV - Serum levels of calcineurin inhibitor (Tacrolimus) of kidney transplant patients seen by the Pharmaceutical Care 
Service. April - October/2011, Fortaleza - Ceará
KIDNEY TRANSPLANT 
TIME AFTER 
TRANSPLANT
TACROLIMUS 
(serum level, ng/mL)
No. OF PATIENTS 
(%)
TACROLIMUS PROTOCOL2 
(serum level, ng/mL)
1st - 2nd month 8 16 (29.0) 8-10 
3rd - 6th month 6 21 (38.2) 6-8 
7th - 12th month 6 15 (27.3) 5-7 
> 12 months 3 3 (5.5%) 3-5 
TOTAL 55 (100%)
2Protocol of kidney transplant UNIT of Walter Cantídio University Hospital – Version 2011.
FIGURE 2 - Negative Outcomes associated with Medication (NOM) identified by the Pharmaceutical Care Service for kidney and 
liver transplant patients. April – October/2011, Fortaleza – Ceará.
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TABLE V - Classification according to Sabater et al. (2005) and Riba et al. (2000) of pharmaceutical interventions performed by 
the Pharmaceutical Care Service for kidney transplant patients in the period of April/2011 – October/2011 in Fortaleza – Ceará
Classification of PI types according 
to Sabater et al.3 n (%)
Classification of significance of PI 
according to Riba et al.3 n (%)
Intervention in education of patient on treatment 111 (80) “Significant” 116 (83.4)
Intervention in dose of medication 15 (11) “Very significant” 10 (7.2)
Intervention in pharmacological strategy 13 (9) “Extremely significant” 13 (9.4)
TOTAL 139 (100)  139 (100)
3 p<0.05, X² test
TABLE VI - Pharmaceutical interventions (n=139) (P8a) performed bythe Pharmaceutical Care Service for kidney and liver transplant 
patients in the period of April – October/2011 in Fortaleza – Ceará
PHARMACEUTICAL INTERVENTIONS N (%) 
(p<0.05, X² test)
Guidance on pharmacotherapeutic treatment 95 (68)
Request to suspend unnecessary medication 10 (7)
Adapt schedule of administration 9 (6)
Access of patient to pharmacological treatment 12 (9)
Guidance on the appropriate manner of administration of prescribed medication 6 (4)
Request to correct dose of prescribed medication 2 (1)
Request to change dosage of prescribed medication 4 (3)
Referral to nutritionist 1 (1)
TOTAL 139 (100)
FIGURE 3 - Classes contacted in Pharmaceutical Interventions carried out by the Pharmaceutical Care Service for kidney and liver 
transplant patients in the period of April – October/2011 in Fortaleza – Ceará.
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consta nas References. Providenciar!) all interventions 
were “appropriate,” where 83.4% (n=116; p<0.05) of 
pharmaceutical interventions performed in the study 
period were found to be “significant” (Table VI).
DISCUSSION
On analyzing the epidemiological profile of these 
patients, it was evident that there was a predominance 
of male patients, older than 40 years with incomplete 
primary education. It has been noted in the literature that 
age and level of education of patients who undergo chronic 
treatment influence adherence to the pharmacotherapy 
regimen instituted (Lima, Soler, Meiners, 2010). The 
education profile of the sample analyzed was similar to 
that of the study of Moreira (2008), in which the majority 
of patients with chronic renal disease interviewed were 
illiterate or had at most a primary education level (68.5%). 
In the case of complicated treatment such as that in post-
transplant, it is essential to have a caretaker with a more 
advanced level of education, but it is usually a family 
member who assumes this role. Thus, the role of the 
caretaker is strongly influenced by the degree of kinship 
and gender (Melo, Rodrigues, Schmidt, 2009).
The treatment instituted in liver and/or kidney 
post-transplant care is very complex, and in this study 
the patients needed to take on average seven different 
medications daily. As adherence to treatment is of utmost 
importance for the success of the transplant, it is necessary 
that these patients receive a specific care with adequate 
guidance. The utilization of many medications increases 
the chances of these patients developing adverse effects, 
as well as occurrence of drug interactions culminating in 
the abandonment of treatment and thus non-adherence 
(Schroeter et al., 2007).
The determination of blood immunosuppressant 
levels is important in the pharmacotherapeutic monitoring 
of transplant patients, because besides checking for toxic 
drug concentrations, it is also possible to monitor the 
patient’s adherence to the treatment. In the study period, 
there were only three patients in the sample studied who 
did not show tacrolimus levels within those recommended 
in the protocol, which indicated statistical significance 
when compared to the other groups (p<0.05). The routine 
monitoring of blood immunosuppressant levels aids in 
adjusting the dose to maintain the maximal efficacy with 
minimal toxicity (Brahm, 2012). It should be considered 
that some patients have an individual desired target, which 
can be below or above the range considered therapeutic. 
A study by Chisholm et al. (2001) showed that the 
group of post-renal transplant patients who received 
pharmacotherapeutic monitoring by a pharmacist had a 
greater adherence to treatment compared to the group of 
patients who did not receive such care.
The study conducted by Albert (2010), showed 
that a Pharmaceutical Care Program in which the clinical 
pharmacist worked together with a multidisciplinary 
team in the care of liver transplant patients allowed 
the identification, prevention and resolution of DRP, 
preventing adverse effects caused by pharmacotherapy 
and facil i tat ing an appropriate guidance in the 
pharmacotherapy instituted. During the care of the 
patients by the Pharmaceutical Care service in a university 
hospital, guidance in the treatment instituted always paid 
close attention to the dose and schedule of administration 
of medications, but also identified NOM, which are effects 
on the health of the patient not adequately treated and 
which are associated with the use of medications; these 
NOM were determined by the existence of one or more 
DRP. The majority of interventions were done directly 
with the patient because they showed untreated health 
problems, where the interventions involved guidance in 
the treatment instituted, showing statistical significance 
compared to other interventions (p<0.05) the majority 
related to the access to the treatment and/or to non-
adherence to the treatment.
Through pharmaceutical interventions, access of 
the patient to the treatment instituted was guaranteed, 
besides the assurance of its appropriate execution. The 
pharmacist of the Pharmaceutical Care service also 
performed important interventions when suspending 
unnecessary medications, always based on the protocol 
of two outpatient departments and clinical outcome of 
the patients and aimed at guaranteeing the rational use of 
medications. In relation to significance, a large portion 
of interventions were classified as “significant,” because 
they were interventions that improved the care of the 
patient, resulting in enhanced quality of care. Still, some 
were classified as “extremely significant” because they 
were instrumental in a very important increase in efficacy 
or in quality of therapy, while others were categorized as 
“very significant” since they increased drug effectiveness 
or decreased toxicity, leading to an enhanced quality of 
life for the patient. In a study conducted in a post-kidney 
transplant unit in Georgia, 76.4% of pharmaceutical 
interventions were classified as “significant,” where 28.6% 
were related to an untreated health problem and 26.6% to 
the dose of the medication (Chisholm, 2000).
Pharmaceutical Care encompasses all the activities 
conducted by the pharmacist assigned to the patient, with 
the objective of achieving the maximal benefit of the 
proposed pharmacotherapy, as well as promoting measures 
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that improve health and prevent diseases (Dader, Muñoz, 
Martinez-Martinez, 2008).
CONCLUSION
The pharmacist of the Pharmaceutical Care service 
for the transplant patients was capable of carrying out 
interventions on the pharmacotherapy instituted, where 
these were for the most part “significant” by increasing 
the quality of care provided to the patient. Besides, the 
risks of the occurrence of negative outcomes associated 
with medication observed might be diminished, being 
considered a possible benefit from the pharmaceutical 
care service provided.
It is concluded that the pharmacist, through 
Pharmaceutical Care, provides guidance with respect to 
prescribed medications, monitors the pharmacotherapy, 
and intervenes when necessary, thereby establishing his/
her part in the multiprofessional team.
REFERENCES
AGUIAR, P.M.; BALISA-ROCHA, B.J.; BRITO GDE, 
C.; SILVA, W.B.; MACHADO, M.; LYRA JR., D.P. 
Pharmaceutical care in hypertensive patients: a systematic 
literature review. Res. Social Adm. Pharm., v.8, n.5, p.383-
396, 2012.
ALBERT, A.R. Evaluación de un Programa de Atención 
Farmacéutica en pacientes sometidos a trasplante hepático. 
Pharm. care Esp., v.12, n.3, 2010, p.99-109.
AMARAL, M.F.Z.J.; AMARAL, R.G.; PROVIN, M.P. 
Intervenção farmacêutica no processo de cuidado 
farmacêutico: uma revisão. Rev. Eletr. Farm., v.5, n.1, 
p.60-66, 2008.
BARCELOS, S.; DIAS, A.L.; FORGIARINI-JÚNIOR, L.A.; 
MONTEIRO, B.M. Transplante hepático: repercussões na 
capacidade pulmonar, condição funcional e qualidade de 
vida. Arq. Gastroenterol., v.45, n.3, p.186-191, 2008.
BERQUIST, R.K.; BERQUIST, W.E.; ESQUIVEL, C.O.; COX, 
K.L.; WAYMAN, K.I.; LITT, I.F. Non-adherence to post-
transplant care: prevalence, risk factors and outcomes in 
adolescent liver transplant recipients. Pediatr. Transplant., 
v.12, n.2, p.194-200, 2008.
BORGES, M.C.L.A.; BATISTA, M.O.R.; RODRIGUES, 
A.M.M.; CARVALHO, O.M.C. Transplante de fígado no 
Ceará caracterização da população atendida em 2007. R. 
Pesq.: Cuid. Fundam. Online, Brasil, suppl.2, p.5-7, 2010.
BRAHM, M.M.T. Adesão aos imunossupressores em 
pacientes transplantados renais. Porto Alegre, 2012. 102 
p. [Dissertation of Master degree. Department of Medical 
Sciences, Federal University of Rio Grande do Sul].
BRASIL. Ministério da Saúde. Secretaria de Ciência, Tecnologia 
e Insumos estratégicos. Departamento de Assistência 
Farmacêutica e Insumos Estratégicos. A Universidade 
construindo o farmacêutico generalista para o SUS. In: 
Fórum Nacional de Ensino e as Pesquisa da Atenção 
Farmacêutica no Âmbito do SUS, 1. Anais do 1º Fórum 
nacional de ensino e pesquisa da atenção farmacêutica no 
âmbito do SUS “A universidade construindo o farmacêutico 
generalista para o SUS”. Brasília, 2007.
CASTRO, M.S.; CHEMELLO, C.; PILGER, D.; JUNGES, 
F.; BOHNEN, L.; ZIMMERMAN, L.M.; PAULINO, 
M.A.; JACOBS, U.; FERREIRA, M.B.C.; FUCHS, F.D. 
Contribuição da atenção farmacêutica no tratamento de 
pacientes hipertensos. Rev. Bras. Hipertens., v.13, n.3, 
p.198-202, 2006.
CEARÁ. Secretária da Saúde do Ceará (Org.). Ceará atinge 
pela primeira vez marca de 1.000 transplantes ano. 
Available at: <http://www.saude.ce.gov.br/index.php/
noticias/45032-Ceará-supera-pela-primeira-vez-marca-de-
1000-transplantes-ano->. Accessed on: Nov. 2011.
CHISHOLM, M.A.; VOLLENWEIDER, L.J.; MULLOY, 
L.L.; JAGADEESAN, M.; WADE, W.E.; DIPIRO, J.T. 
Direct patient care services provided by a pharmacist on a 
multidisciplinary renal transplant team. Am. J. Health Syst. 
Pharm., v.57, n.21, p.1599-1601, 2000.
CHISHOLM, M.A.; MULLOY, L.L.; JAGADEESAN, M.; 
DIPIRO, J.T. Impact of clinical pharmacy services on renal 
transplant patients’ compliance with immunosuppressive 
medications. Clin. Transplant., v.15, n.5, p.330-336, 2001.
COLLINS, C.; LIMONE, B.L.; SCHOLLE, J.M.; COLEMAN, 
C.I. Effect of pharmacist intervention on glycemic control. 
Diabetes Res. Clin. Pract., v.92, n.2, p.145-152, 2010.
B. C. C. Martins, T. R. Souza, A. M. P. T. Luna, M. M. F. Fonteles, P. Y. M. Firmino, P. F. C. B. C. Fernandes, J. H. P. Garcia, C. M. C. Oliveira, E. D. R. Néri668
COMITÉ DE CONSENSO GIAF-UGR, GIFAF-USE, GIF-
UGR. Tercer consenso de Granada sobre problemas 
relacionados con medicamentos y resultados negativos 
asociados a la medicación. Ars Pharm., v.1, n.48, p.5-17, 
2007.
CUNHA, C.B.; LEÓN, A.C.P.; SCHRAMM, J.M.A.; 
CARVALHO, M.S; SOUZA JR, P.R.B.; CHAIN, R. Tempo 
até o transplante e sobrevida. Cad. Saúde Pública, v.4, n.23, 
p.805-812, 2007.
DÁDER, M.J.F.; MUÑOZ, P.M.; MARTINEZ-MARTINEZ, 
F. Problemas relacionados com medicamentos (PRM) e 
resultados negativos associados ao medicamento (RNM). 
In: DÁDER, M.J.F.; MUÑOZ, P.A.; MARTINEZ-
MARTINEZ, F. (Eds.). Atenção farmacêutica: conceitos, 
processos e casos. Espanha:(Verificar cidade da Espanha 
com os autores) Rcn Comercial e Editora, 2008. cap.2, 
p.49-59.
HERNANZ, B.C. Detección resultados negativos asociados a la 
medicación de pacientes de la Unidad de Observación del 
Área de Urgencias. Granada, 2007. 191 f. [Thesis of PhD 
degree. Faculty of Pharmaceutical Sciences, University of 
Gramado].
HOSPITAL UNIVERSITÁRIO WALTER CANTÍDIO (Brasil). 
Transplante. Available at: <www.huwc.ufc.br>. Accessed 
on: June 2012.
KABOLI, P.J.; HOTH, A.B.; MCCLIMON, B.J.; SCHNIPPER, 
J.L. Clinical pharmacists and inpatient medical care: a 
systematic review. Arch. Intern. Med., v.166, n.9, p.955-
964, 2006.
LIMA, T.M.; MEINERS, M.M.M.A.; SOLER, O. Perfil de 
adesão ao tratamento de pacientes hipertensos atendidos 
na Unidade Municipal de Saúde de Fátima, em Belém, 
Pará, Amazônia, Brasil. Rev. Pan-amaz. Saúde, v.1, n.2, 
p.113-120, 2010.
MACHUCA, M.; FERNÁNDEZ-LLIMÓS, F.; FAUS, M.J. 
Método dáder: guía de seguimiento fármacoterapéutico.
Granada: GIAF-UGR, 2003. 128 p.
MELO, T.M.; RODRIGUES, I.G.; SHIMIDT, D.R.C. 
Caracterização dos cuidadores de pacientes em cuidados 
paliativos no domicílio. Rev. Bras. Cancerol., v.55, n.4, 
p.365-374, 2009.
MOREIRA, L.B.; FERNANDES, P.F.C.B.C.; MONTE, F.S.; 
MARTINS, A.M.C. Adesão ao tratamento farmacológico 
em pacientes com doença crônica. J. Bras. Nefrol., v.30, 
n.2, p.113-119, 2008.
RIBA, R.F.; ESTELA, A.C.; ESTEBAN, M.L.S.; CELS, 
I.C; LECHUGA, M.G.; SÁNCHEZ, S.L.; SANZ, 
R.T.; ARANDA, G.A.; ÁLVAREZ, F.C.; PELÁEZ, 
M.G.; ARCUSA, O.M.; SOLER, G.S.; MAZÓ, M.S. 
Intervenciones farmacêuticas (parte I): metodología y 
evaluación. Farm. Hosp., v.24, n.3, p.136-144, 2000.
ROVERS, J.P.; CURRIE, J.D. Guia prático da atenção 
farmacêutica: manual de habilidades clínicas. São Paulo: 
Pharmabooks, 2010.305 p.
SABATER, D.; FERNANDEZ-LLIMOS, F.; PARRAS, M.; 
FAUS, M.J. Tipos de intervenciones farmacéuticas en 
seguimiento farmacoterapéutico. Seguimiento(Autores 
providenciar nomenclatura) Farmacoterapéutico, v.3, n.2, 
p.90-97, 2005. 
SCHROETER, G.; TROMBETTA, T.; FAGGIANI, F.T.; 
GOULART, P.V.; CREUTZBERG, M.; VEIGAS, K.; 
SOUZA, A.C.A.; CARLI, G.A.; MORRONE, F.B. Terapia 
anti-hipertensiva utilizada por pacientes idosos de Porto 
Alegre/RS, Brasil. Sci. Medica, v.17, n.1, p.14-19, 2007.
SIMONI, C.R. Avaliação do impacto de métodos de Atenção 
Farmacêutica. 2009. Porto Alegre, 2009. 183 f. [Dissertion 
of Master degree. Faculty of Pharmacy, Federal University 
of Rio Grande do Sul].
WANG, H.Y.; CHAN, A.L.F.; CHEN, M.T.; LIAO, C.H.; TIAN, 
Y.F. Effects of pharmaceutical care intervention by clinical 
pharmacists in renal transplant clinics. Transplant. Proc., 
v.40, n.7, p.2319-2323, 2008.
WORLD HEALTH ORGANIZATION. Anatomical Therapeutic 
Chemical (ATC). Available at: <http://www.whocc.no/
atc_ddd_index/>. Accessed on: Aug. 2012
WORLD HEALTH ORGANIZATION.  Deve lop ing 
p h a r m a c y  p r a c t i c e :  a  f o c u s  o n  p a t i e n t  c a r e : 
handbook, 2006. Available at: <http://www.fip.org/
files/fip/publications/DevelopingPharmacyPractice/
DevelopingPharmacyPracticeEN.pdf>. Accessed on: Sept., 
2012.
Received for publication on 09th October 2012
Accepted for publication on 15th August 2013
